Cardiac microRNA-133 is down-regulated in thyroid hormone-mediated cardiac hypertrophy partially via Type 1 Angiotensin II receptor

GP Diniz, CA Lino, EC Guedes… - Basic Research in …, 2015 - Springer
GP Diniz, CA Lino, EC Guedes, L Nascimento Moreira, MLM Barreto-Chaves
Basic Research in Cardiology, 2015Springer
Elevated thyroid hormone (TH) levels induce cardiac hypertrophy partially via type 1
Angiotensin II receptor (AT1R). MicroRNAs (miRNAs) are key regulators of cardiac
homeostasis, and miR-133 has been shown to be involved in cardiac hypertrophy. However,
the potential role of miR-133 in cardiac growth induced by TH is unknown. Thus, we aimed
to investigate the miR-133 expression, as well as its potential role in cardiac hypertrophy in
response to TH. Wistar rats were subjected to hyperthyroidism combined or not with the …
Abstract
Elevated thyroid hormone (TH) levels induce cardiac hypertrophy partially via type 1 Angiotensin II receptor (AT1R). MicroRNAs (miRNAs) are key regulators of cardiac homeostasis, and miR-133 has been shown to be involved in cardiac hypertrophy. However, the potential role of miR-133 in cardiac growth induced by TH is unknown. Thus, we aimed to investigate the miR-133 expression, as well as its potential role in cardiac hypertrophy in response to TH. Wistar rats were subjected to hyperthyroidism combined or not with the AT1R blocker. T3 serum levels were assessed to confirm the hyperthyroid status. TH induced cardiac hypertrophy, as evidenced by higher cardiac weight/tibia length ratio and α-actin mRNA levels, which was prevented by AT1R blocker. miR-133 expression was decreased in TH-induced cardiac hypertrophy in part through the AT1R. Additionally, the cardiac mRNA levels of miR-133 targets, SERCA2a and calcineurin were increased in hyperthyroidism partially via AT1R, as evaluated by real-time RT-PCR. Interestingly, miR-133 levels were unchanged in T3-induced cardiomyocyte hypertrophy in vitro. However, a gain-of-function study revealed that miR-133 mimic blunted the T3-induced cardiomyocyte hypertrophy in vitro. Together, our data indicate that miR-133 expression is reduced in TH-induced cardiac hypertrophy partially by the AT1R and that miR-133 mimic prevents the cardiomyocyte hypertrophy in response to T3 in vitro. These findings provide new insights regarding the mechanisms involved in the cardiac growth mediated by TH, suggesting that miR-133 plays a key role in TH-induced cardiomyocyte hypertrophy.
Springer